In recent years, many Alzheimer’s drugs have failed in clinical trials, their efficacy and safety. A new drug that acts differently than the previously-tested drugs, was well tolerated in a first clinical study good and rated as safe.
Four weeks of healthy study participants tolerated the new drug daily taken, and well. This was achieved in the blood concentrations of active Ingredient which had been proven in animal tests to be effective. In the next step, the effect of the drug should now be tested on Alzheimer’s patients.
Prior to this, the ingredient called PRI had achieved-002 in animal experiments, good results: "We were able to show that mice with Alzheimer’s-like symptoms to a cognitive performance improvement. Memory and mental performance of the treated mice improved significantly compared with the Placebo group, and were not even from the memory to unterscheiden" healthy mice;, Dr. Janine Kutzsche, a scientist from the Team of Prof. Willbold from the Institute for structural biochemistry, Jülich says.
Other previously failed candidates for Alzheimer’s therapy should inhibit the formation of Amyloid-beta, a substance that is involved in the pathogenesis of Alzheimer’s disease. These active ingredients could not stand the test, but in clinical studies. In Jülich it is pursued now, the goal is not to prevent the formation of the naturally occurring Amyloid-beta, but the Aggregation as Amyloid-beta aggregates proliferate to self and other in the brain damage. The new active ingredient breaks down the aggregates into individual components.